International Finance and Accounting Handbook

22 • 17

In accordance with IAS 14 (Segment Reporting), a breakdown of certain data in the financial statements is given by segment and g

eographical region. The

segments and regions are the same as those used for internal reporting. The aim is to provide users of the financial statements

with information regarding

the profitability and future prospects of the Group’s various activities. To allow a more accurate appraisal of continuing oper

ations, the discontinuing op-

erations are shown separately.

The Bayer Group is managed on the basis of business groups, which are aggregated into reportable segments according to economic

characteristics, prod-

ucts, production processes, customer relationships and methods of distribution. There are currently 14 business groups, which

are aggregated here into 7

reportable segments.KEY DATA BY SEGMENT (1)

Health Care

Agriculture

Polymers Chemicals

Polyurethanes,

Pharmaceuticals &

Consumer Care &

Crop

Animal

Plastics &

Coatings &

Reportable Segments

Biological Products

Diagnostics

Protection

Health

Rubber

Colorants

Chemicals

Euros in millions—2001Net sales (external)

5,729

4,104

2,708

988

5,581

5,207

3,749

• Change in euros

–6.7%

+5.6%

+10.3%

–1.1%

–4.0%

+2.6%

+9.9%

• Change in local currencies

–6.7%

+5.0%

+10.7%

–1.1%

–5.0%

+2.1%

10.0%

Intersegment sales

38

2

102

5

116

138

456

Other operating income

62

49

102

13

87

51

53

Operating result before exceptionals

383

388

453

172

288

146

271

Return on sales before exceptionals

6.7%

9.5%

16.7%

17.4%

5.2%

2.8%

7.2%

Exceptional items

(332)

(47)

0

0

(50)

(100)

(68)

Operating result

51

341

453

172

238

46

203

Return on sales

0.9%

8.3%

16.7%

17.4%

4.3%

0.9%

5.4%

Gross cash flow

229

534

550

163

587

614

379

Capital invested

5,352

3,799

3,884

645

6,405

8,051

4,774

CFROI

4.2%

14.0%

13.9%

22.8%

8.9%

7.5%

7.7%

Equity-method income

0

0

0

0

0

0

0

Equity-method investments

16

0

0

0

27

773

13

Total assets

5,303

3,956

3,488

734

5,867

7,493

4,216

Capital expenditures

415

267

215

49

592

492

483

Amortization and depreciation

364

291

247

40

482

604

334

Liabilities

1,869

1,271

1,130

379

1,339

2,311

1,797

Research and development expenses

1,242

252

292

98

134

186

114

Number of employees (as of Dec. 31)

26,800

14,900

10,900

3,900

17,900

15,100

19,500

Exhibit 22.4.

Illustration of IAS 14R Segmental Data Provided by Bayer.